Duopharma Biotech Berhad Gestione
Gestione criteri di controllo 3/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Leonard bin Abdul Shatar
Amministratore delegato
RM 2.5k
Compenso totale
| Percentuale dello stipendio del CEO | 47.8% |
| Mandato del CEO | 16.8yrs |
| Proprietà del CEO | n/a |
| Durata media del management | 1.8yrs |
| Durata media del Consiglio di amministrazione | 6.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005
Aug 27
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018
Apr 04Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price
Feb 17These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively
Oct 21Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005
Aug 18Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Aug 07Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year
Mar 28Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Mar 27We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings
Nov 26Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021
Nov 25Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005
Aug 20Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly
May 22Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend
Apr 13A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Mar 14Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly
Feb 12Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?
Jan 28
Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?
Jan 12Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | RM 56m |
| Jun 30 2024 | n/a | n/a | RM 49m |
| Mar 31 2024 | n/a | n/a | RM 45m |
| Dec 31 2023 | RM 3k | RM 1k | RM 53m |
| Sep 30 2023 | n/a | n/a | RM 61m |
| Jun 30 2023 | n/a | n/a | RM 69m |
| Mar 31 2023 | n/a | n/a | RM 72m |
| Dec 31 2022 | RM 2m | RM 1m | RM 70m |
| Sep 30 2022 | n/a | n/a | RM 69m |
| Jun 30 2022 | n/a | n/a | RM 69m |
| Mar 31 2022 | n/a | n/a | RM 68m |
| Dec 31 2021 | RM 2m | RM 1m | RM 66m |
| Sep 30 2021 | n/a | n/a | RM 66m |
| Jun 30 2021 | n/a | n/a | RM 63m |
| Mar 31 2021 | n/a | n/a | RM 63m |
| Dec 31 2020 | RM 2m | RM 924k | RM 59m |
| Sep 30 2020 | n/a | n/a | RM 54m |
| Jun 30 2020 | n/a | n/a | RM 55m |
| Mar 31 2020 | n/a | n/a | RM 54m |
| Dec 31 2019 | RM 2m | RM 882k | RM 55m |
| Sep 30 2019 | n/a | n/a | RM 58m |
| Jun 30 2019 | n/a | n/a | RM 55m |
| Mar 31 2019 | n/a | n/a | RM 51m |
| Dec 31 2018 | RM 1m | RM 876k | RM 48m |
Compensazione vs Mercato: La retribuzione totale di Leonard ($USD 567.40 ) è inferiore alla media delle aziende di dimensioni simili nel mercato MY ($USD 153.60K ).
Compensazione vs guadagni: La retribuzione di Leonard è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Leonard bin Abdul Shatar (59 yo)
16.8yrs
Mandato
RM 2,533
Compensazione
Encik Ariff bin Abdul Shatar, also known as Leonard, has been Group Managing Director of Duopharma Biotech Berhad (alternate name Duopharma Biotech Bhd) since December 28, 2017. Encik bin Abdul Shatar serv...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Group MD & Executive Director | 16.8yrs | RM 2.53k | Nessun dato | |
| Chief Financial Officer | 12.3yrs | Nessun dato | 0.000010% MYR 120.2 | |
| Chief Executive Officer of Group Operations | less than a year | Nessun dato | Nessun dato | |
| Chief Legal Officer & Group Company Secretary | 6.9yrs | Nessun dato | Nessun dato | |
| Chief Compliance Officer | 1.3yrs | Nessun dato | Nessun dato | |
| Chief Manufacturing & Sustainability Officer | 2.1yrs | Nessun dato | 0.00030% MYR 3.6k | |
| Chief Consumer Healthcare Officer | less than a year | Nessun dato | Nessun dato | |
| Group Head of Risk Management & Integrity | 1.8yrs | Nessun dato | Nessun dato | |
| Chief Innovation Officer | less than a year | Nessun dato | Nessun dato |
1.8yrs
Durata media
54yo
Età media
Gestione esperta: Il team dirigenziale di DPHARMA non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Group MD & Executive Director | 6.9yrs | RM 2.53k | Nessun dato | |
| Independent Non-Executive Director | less than a year | Nessun dato | Nessun dato | |
| Independent Non-Executive Director | 8.4yrs | RM 130.80k | Nessun dato | |
| Non Independent Non Executive Director | 6.7yrs | RM 146.40k | 0.0026% MYR 31.6k | |
| Independent Non-Executive Director | 6.9yrs | RM 143.80k | Nessun dato | |
| Independent Non-Executive Director | 5.2yrs | RM 135.40k | Nessun dato | |
| Independent Non Executive Director | 8.2yrs | RM 143.80k | Nessun dato | |
| Senior Independent Non-Executive Director | 8yrs | RM 141.40k | Nessun dato | |
| Non-Independent & Non-Executive Chairman | 1.4yrs | RM 76.70k | Nessun dato | |
| Non Independent & Non Executive Alternate Director | 1.3yrs | Nessun dato | Nessun dato | |
| Non-Independent & Non-Executive Director | less than a year | Nessun dato | Nessun dato |
6.7yrs
Durata media
64yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di DPHARMA sono considerati esperti (durata media dell'incarico 6.7 anni).